MitoRx’s Lead Molecule Reverses Mitochondrial Loss in Obese Mice

MTRX31’s Mechanism: Targeting the Mitochondrial Biogenesis Pathway

MitoRx Therapeutics announced pre‑clinical evidence that its small‑molecule drug, MTRX31, can restore mitochondrial density in the livers of diet‑induced obese mice. The data were presented at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting in Milan on 30 September 2026, following a study conducted at the University of Oxford.

The research involved feeding mice a high‑fat diet for 12 weeks to induce obesity and liver steatosis, then treating them with oral MTRX31 for four weeks. Transmission electron microscopy (TEM) images revealed a marked increase in the number and size of mitochondria in the liver cells of treated animals. Quantitative analysis showed a 45 % rise in mitochondrial volume density compared with untreated controls, suggesting that MTRX31 can reverse the mitochondrial depletion that accompanies fatty liver disease.

MitoRx’s scientists explain that MTRX31 activates the PGC‑1α pathway, a key regulator of mitochondrial biogenesis. By enhancing the transcription of genes involved in mitochondrial replication and function, the compound promotes the formation of new, healthy mitochondria. The TEM images support this mechanism, displaying more densely packed, crista‑rich organelles in treated livers. The team also noted improved oxidative phosphorylation capacity, measured by increased ATP production in isolated hepatocytes.

Can This Approach Translate to Human Patients?

The study’s authors highlighted that the restoration of mitochondrial density correlated with reduced liver triglyceride content and improved insulin sensitivity in the mice. „We see a clear link between mitochondrial health and metabolic resilience,” said Dr. Elena Rossi, lead investigator. „MTRX31 not only replenishes mitochondria but also restores their functional capacity, which is critical for treating non‑alcoholic fatty liver disease.”

The question remains whether the same mitochondrial benefits will appear in humans. While mouse models provide valuable proof of concept, human trials are necessary to confirm safety, dosing, and efficacy. MitoRx plans to initiate a Phase I study later this year, enrolling healthy volunteers to assess pharmacokinetics and tolerability. If successful, the company will move to a Phase II trial in patients with non‑alcoholic steatohepatitis (NASH) to evaluate liver function and histology.

The company’s presentation also touched on potential off‑target effects. Preliminary toxicity studies in rodents showed no significant organ damage or behavioral changes at therapeutic doses. However, long‑term safety data will be essential before the drug can reach the clinic.

The implications of these findings are significant. Mitochondrial dysfunction is a hallmark of many metabolic diseases, and a drug that can safely restore mitochondrial density could alter the treatment landscape for NASH and related disorders. Moreover, the oral formulation of MTRX31 offers a convenient route of administration, potentially improving patient adherence.

Frequently Asked Questions

What is the main benefit of MTRX31 in the mouse study? MTRX31 increased liver mitochondrial density by 45 % and improved insulin sensitivity, indicating a reversal of obesity‑induced mitochondrial loss.

How does MTRX31 work at the cellular level? It activates the PGC‑1α pathway, promoting mitochondrial biogenesis and enhancing oxidative phosphorylation, which restores energy production in liver cells.

When will human trials begin? MitoRx plans a Phase I safety study in healthy volunteers later this year, followed by a Phase II trial in NASH patients if the first phase is successful.